SNAI2 promotes the development of ovarian cancer through regulating ferroptosis

References

• Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1511–1518.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Liang C, Zhang X, Yang M, et al. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31(51):e1904197.
   PubMed Web of Science ®Google Scholar
• Li Z, Chen L, Chen C, et al. Targeting ferroptosis in breast cancer. Biomark Res. 2020;8(1):58.
   PubMed Web of Science ®Google Scholar
• You Y, Fan Q, Huang J, et al. Ferroptosis-related gene signature promotes ovarian cancer by influencing immune infiltration and invasion. J Oncol. 2021;2021:9915312.
   PubMed Web of Science ®Google Scholar
• Yu Z, He H, Chen Y, et al. A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma. Sci Rep. 2021;11(1):11486.
   PubMed Web of Science ®Google Scholar
• Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–698.
   PubMed Web of Science ®Google Scholar
• Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180–1191.
   PubMed Web of Science ®Google Scholar
• Cao JY, Poddar A, Magtanong L, et al. A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. Cell Rep. 2019;26(6):1544–56 e8.
   PubMed Web of Science ®Google Scholar
• Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1–2):317–331.
   PubMed Web of Science ®Google Scholar
• Casas E, Kim J, Bendesky A, et al. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011;71(1):245–254.
   PubMed Web of Science ®Google Scholar
• Uygur B, Abramo K, Leikina E, et al. SLUG is a direct transcriptional repressor of PTEN tumor suppressor. Prostate. 2015;75(9):907–916.
   PubMed Web of Science ®Google Scholar
• Fan H, Wang X, Li W, et al. ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP. Genes Dev. 2020;34(19–20):1359–1372.
   PubMed Web of Science ®Google Scholar
• Alves CC, Carneiro F, Hoefler H, et al. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci (Landmark Ed). 2009;14:3035–3050.
   PubMed Web of Science ®Google Scholar
• Shioiri M, Shida T, Koda K, et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer. 2006;94(12):1816–1822.
   PubMed Web of Science ®Google Scholar
• Shih JY, Tsai MF, Chang TH, et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11(22):8070–8078.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang X, Xu S, et al. Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression. Mol Cancer. 2017;16(1):163.
   PubMed Web of Science ®Google Scholar
• Li J, Li S, Chen R, et al. Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. Oncotarget. 2017;8(6):9672–9685.
   PubMedGoogle Scholar
• Chen W, Wang H, Liu J, et al. Interference of KLF9 relieved the development of gestational diabetes mellitus by upregulating DDAH2. Bioengineered. 2021. DOI:10.1080/21655979.2021.2005929
   Web of Science ®Google Scholar
• Hao S, Yu J, He W, et al. Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells. Neoplasia. 2017;19(12):1022–1032.
   PubMed Web of Science ®Google Scholar
• Huo H, Zhou Z, Qin J, et al. Erastin disrupts mitochondrial permeability transition pore (mPTP) and induces apoptotic death of colorectal cancer cells. PLoS One. 2016;11(5):e0154605.
   PubMed Web of Science ®Google Scholar
• Li L, Qiu C, Hou M, et al. Ferroptosis in ovarian cancer: A novel therapeutic strategy. Front Oncol. 2021;11:665945.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lin J, Xiong Y, et al. Superparamagnetic iron oxide nanoparticles induce ferroptosis of human ovarian cancer stem cells by weakening cellular autophagy. J Biomed Nanotechnol. 2020;16(11):1612–1622.
   PubMed Web of Science ®Google Scholar
• Dixon SJ. Ferroptosis: bug or feature? Immunol Rev. 2017;277(1):150–157.
   PubMed Web of Science ®Google Scholar
• Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36(29):4089–4099.
   PubMed Web of Science ®Google Scholar
• Kouba S, Ouldamer L, Garcia C, et al. Lipid metabolism and calcium signaling in epithelial ovarian cancer. Cell Calcium. 2019;81:38–50.
   PubMed Web of Science ®Google Scholar
• Zhou HH, Chen X, Cai LY, et al. Erastin reverses ABCB1-Mediated docetaxel resistance in ovarian cancer. Front Oncol. 2019;9:1398.
   PubMed Web of Science ®Google Scholar
• Li M, Wang X, Lu S, et al. Erastin triggers autophagic death of breast cancer cells by increasing intracellular iron levels. Oncol Lett. 2020;20(4):57.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Yasui H, Higashikawa K, et al. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PLoS One. 2019;14(12):e0225931.
   PubMed Web of Science ®Google Scholar
• Sun D, Li YC, Zhang XY. Lidocaine promoted ferroptosis by targeting miR-382-5p /SLC7A11 axis in ovarian and breast cancer. Front Pharmacol. 2021;12:681223.
   PubMed Web of Science ®Google Scholar
• Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928.
   PubMed Web of Science ®Google Scholar
• Fan L, Lei H, Zhang S, et al. Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10. Theranostics. 2020;10(13):5895–5913.
   PubMed Web of Science ®Google Scholar
• Findlay VJ, Wang C, Nogueira LM, et al. SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther. 2014;13(11):2713–2726.
   PubMed Web of Science ®Google Scholar